No Data
Jafron Biomedical Co.,Ltd. Just Missed Revenue By 8.1%: Here's What Analysts Think Will Happen Next
Jianfan Biotech: Report for the third quarter of 2024
Jafron Biomedical (300529.SZ) released its performance for the first three quarters, with a net income of 0.792 billion yuan, an 86.86% year-on-year increase.
Jafron Biomedical (300529.SZ) released the third quarter report for 2024, with revenue for the first three quarters of the company totaling 21...
Jafron Biomedical (300529.SZ): The net income in the third quarter was 0.239 billion yuan, a year-on-year increase of 63.62%.
Gelonghui October 18th, Jafron Biomedical (300529.SZ) announced the third quarter report for 2024, with revenue of 0.7 billion yuan for the reporting period, a year-on-year increase of 47.74%; net income attributable to shareholders of the listed company was 0.239 billion yuan, a year-on-year increase of 63.62%; net income attributable to shareholders of the listed company after deducting non-recurring gains and losses was 0.228 billion yuan, a year-on-year increase of 61.34%; basic earnings per share of 0.3 yuan.
There Are Reasons To Feel Uneasy About Jafron BiomedicalLtd's (SZSE:300529) Returns On Capital
Jafron Biomedical Co.,Ltd. (SZSE:300529) Stocks Shoot Up 31% But Its P/E Still Looks Reasonable
Jafron BiomedicalLtd's (SZSE:300529) Earnings Trajectory Could Turn Positive as the Stock Increases 7.1% This Past WeekNo Data
No Data
